ANN:ASXAnsell Limited Analysis

Ansell Limited (ANN.AX) is trading at AUD 25.48, comfortably below its 20‑day (≈26.04), 50‑day (≈27.67) and 200‑day (≈32.34) simple moving averages, signalling a short‑term bearish bias. The 14‑day RSI sits at 35.7, edging toward oversold territory, while the MACD histogram has turned positive, giving a tentative bullish signal. Support is anchored around AUD 25.05 and resistance near AUD 27.16, leaving limited upside in the immediate range. Volatility over the past 30 days is elevated at roughly 21 %, and trading volume has been declining, which may exacerbate price swings. Despite the technical weakness, the stock carries a solid dividend yield of 3.16 % with a payout ratio of just over 50 %, indicating cash‑flow coverage. Valuation metrics are attractive: the trailing PE of 19.5 is well below the industry average of 27.2, and the forward PE of 11.8 points to expected earnings acceleration. Analyst consensus targets around AUD 34.9 suggest a potential upside of roughly 35‑40 % from current levels.
Fundamentally, revenue growth is modest at 0.7 % and margins are moderate (gross 42 %, operating 14 %), but ROE and ROA are low, reflecting limited profitability efficiency. The balance sheet shows a net‑debt position of about AUD 584 million, with a debt‑to‑equity ratio of 41.6 %, which is manageable given the company’s cash generation (free cash flow ≈ AUD 114 million). The low beta of 0.54 indicates limited sensitivity to broader market moves, while the healthcare segment provides defensive exposure, though the industrial segment adds some cyclical risk. Regulatory environments for medical devices are stringent, adding a medium level of compliance risk. Geographically the business is diversified across APAC, Europe, the Americas and the Middle East, mitigating single‑region exposure. Overall, the combination of an undervalued price, attractive dividend and defensive sector positioning supports a longer‑term buy case, while short‑term caution is warranted.